Questcor to Present At the 2008 BMO Capital Markets Focus On Healthcare Conference...

* Reuters is not responsible for the content in this press release.

Thu Jul 31, 2008 6:03am EDT 

Questcor to Present At the 2008 BMO Capital Markets Focus On Healthcare
Conference in New York

UNION CITY, Calif., July 31, 2008 (PRIME NEWSWIRE) -- Questcor Pharmaceuticals,
Inc. (Nasdaq:QCOR) announced today that it will present at the BMO Capital
Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, 2008 at the
Millennium Broadway Hotel in New York City. Don M. Bailey, President and Chief
Executive Officer, and George Stuart, Chief Financial Officer, will discuss the
Company's business strategy and historical financial performance at 1:15 p.m.
Eastern Time.

Attendance at the conference is by invitation only. A live audio Webcast of
Questcor's presentation may be accessed through the Company's website at
www.questcor.com. An archived replay of the presentation will be available after
the live presentation, and can also be accessed at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two
commercial products, H.P. Acthar(r) Gel ("Acthar") and Doral(r). Acthar
(repository corticotropin injection) is an injectable drug that is approved for
the treatment of certain disorders with an inflammatory component, including the
treatment of exacerbations associated with multiple sclerosis ("MS"). In
addition, Acthar is not indicated for, but is used in treating patients with
infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and
opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological
disorder. Doral is indicated for the treatment of insomnia characterized by
difficulty in falling asleep, frequent nocturnal awakenings, and/or early
morning awakenings. The Company is also developing QSC-001, a unique orally
disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen
for the treatment of moderate to moderately severe pain. For more information,
please visit www.questcor.com.

-0-
CONTACT: Questcor Pharmaceuticals, Inc.
         Don Bailey
         Steve Cartt
         510-400-0700
         IR2@Questcor.com

         EVC Group, Inc.
         Investors
         Doug Sherk
         415-896-6820
         Dahlia Bailey
         415-896-6820
         Media
         Steve DiMattia
         646-201-5447
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.